Next Article in Journal
Advanced Therapy Medicinal Products: Current and Future Perspectives
Previous Article in Journal
Cost-Effectiveness of Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Validation of Disease States in Schizophrenia: Comparison of Cluster Analysis between US and European Populations

by
Katia Thokagevistk
1,
Aurélie Millier
1,*,
Leslie Lenert
2,
Shamil Sadikhov
3,
Santiago Moreno
3 and
Mondher Toumi
4
1
Creativ-Ceutical, Paris, France
2
Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC, USA
3
F. Hoffmann-La Roche Ltd, Basel, Switzerland
4
Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille University, Marseille, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2016, 4(1), 30725; https://doi.org/10.3402/jmahp.v4.30725
Submission received: 14 December 2015 / Revised: 23 May 2016 / Accepted: 30 May 2016 / Published: 20 June 2016

Abstract

Background: There is controversy as to whether use of statistical clustering methods to identify common disease patterns in schizophrenia identifies patterns generalizable across countries. Objective: The goal of this study was to compare disease states identified in a published study (Mohr/Lenert, 2004) considering US patients to disease states in a European cohort (EuroSC) considering English, French, and German patients. Methods: Using methods paralleling those in Mohr/Lenert, we conducted a principal component analysis (PCA) on Positive and Negative Syndrome Scale items in the EuroSC data set (n=1,208), followed by k-means cluster analyses and a search for an optimal k. The optimal model structure was compared to Mohr/Lenert by assigning discrete severity levels to each cluster in each factor based on the cluster center. A harmonized model was created and patients were assigned to health states using both approaches; agreement rates in state assignment were then calculated. Results: Five factors accounting for 56% of total variance were obtained from PCA. These factors corresponded to positive symptoms (Factor 1), negative symptoms (Factor 2), cognitive impairment (Factor 3), hostility/aggression (Factor 4), and mood disorder (Factor 5) (as in Mohr/Lenert). The optimal number of cluster states was six. The kappa statistic (95% confidence interval) for agreement in state assignment was 0.686 (0.670–0.703). Conclusion: The patterns of schizophrenia effects identified using clustering in two different data sets were reasonably similar. Results suggest the Mohr/Lenert health state model is potentially generalizable to other populations.
Keywords: schizophrenia; outcome assessment; disease states; validation; Europe; USA schizophrenia; outcome assessment; disease states; validation; Europe; USA

Share and Cite

MDPI and ACS Style

Thokagevistk, K.; Millier, A.; Lenert, L.; Sadikhov, S.; Moreno, S.; Toumi, M. Validation of Disease States in Schizophrenia: Comparison of Cluster Analysis between US and European Populations. J. Mark. Access Health Policy 2016, 4, 30725. https://doi.org/10.3402/jmahp.v4.30725

AMA Style

Thokagevistk K, Millier A, Lenert L, Sadikhov S, Moreno S, Toumi M. Validation of Disease States in Schizophrenia: Comparison of Cluster Analysis between US and European Populations. Journal of Market Access & Health Policy. 2016; 4(1):30725. https://doi.org/10.3402/jmahp.v4.30725

Chicago/Turabian Style

Thokagevistk, Katia, Aurélie Millier, Leslie Lenert, Shamil Sadikhov, Santiago Moreno, and Mondher Toumi. 2016. "Validation of Disease States in Schizophrenia: Comparison of Cluster Analysis between US and European Populations" Journal of Market Access & Health Policy 4, no. 1: 30725. https://doi.org/10.3402/jmahp.v4.30725

Article Metrics

Back to TopTop